voranigo
(vorasidenib)Servier Pharmaceuticals LLC
Usage: VORANIGO is indicated for treating adults and pediatric patients aged 12 and older with Grade 2 astrocytoma or oligodendroglioma harboring IDH1 or IDH2 mutations, post-surgery (biopsy, sub-total, or gross total resection), as identified by an FDA-approved test.